Journal ArticleOPEN ACCESS

Space for Calaspargase? A new asparaginase for acute lymphoblastic leukemia

Clinical Cancer Research (2020) 26(2) 325-327
DOI: 10.1158/1078-0432.CCR-19-2975
15Citations
Citations of this article
27Readers
Mendeley users who have this article in their library.

Abstract

In December 2018, the FDA approved calaspargase pegol-mknl (Asperlas, Servier Pharmaceuticals) for acute lymphoblastic leukemia (ALL) in children and young adults up to age 21. Asparaginase is a critical component in the treatment of ALL, but the niche for calaspargase within current treatment protocols is unclear.

Cite

CITATION STYLE

APA

Lew, G. (2020). Space for Calaspargase? A new asparaginase for acute lymphoblastic leukemia. Clinical Cancer Research, 26(2), 325–327. https://doi.org/10.1158/1078-0432.CCR-19-2975

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free